CDT Equity Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$37.1MTTM through 30 Jun 2026
Free Cash Flow -$11.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-36.0%ROE
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.34x
Net Debt-$850Knet cash position
Cash & Equivalents$747K
Quality Metrics
Altman Z-Score-1.90
Piotroski F-Score1 / 9
Multi-Year Trend
Diluted EPSFY2025: $-1,178.00
Dividend
No dividend
Capital Allocation
R&D Spend$3.4M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Research and Development | $0 | View detailsCDT Equity continues to focus on identifying, enhancing, and out-licensing therapeutic assets through scientific innovation and strategic partnerships. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.